Vagus Nerve Stimulation (VNS) — Procedure Guide, Recovery & Risks | MyMedicPlus

Vagus nerve stimulation (VNS) is an adjunctive neuromodulation therapy in which a surgically implanted programmable pulse generator — similar in size and concept to a cardiac pacemaker — delivers controlled electrical impulses to the left vagus nerve at programmable intervals, reducing seizure frequency and severity in drug-resistant epilepsy. The vagus nerve (cranial nerve X) carries afferent fibres from the viscera to brainstem nuclei, particularly the nucleus tractus solitarii (NTS); electrical activation of these fibres modulates activity in multiple cortical and subcortical brain networks — including the thalamus, limbic system, and cerebral cortex — through diffuse ascending projections, reducing epileptiform discharge propagation. VNS was first approved by the FDA in 1997 for adjunctive treatment of drug-resistant focal epilepsy in patients aged 12 years and older, and has since received approvals in multiple countries for both epilepsy and treatment-resistant depression (TRD). The system consists of three components: the titanium-encased pulse generator (approximately 5 cm diameter, 6-7 mm thick) implanted subcutaneously in the left chest wall; a bipolar lead that tunnels subcutaneously from the generator up the neck and wraps around the left vagus nerve in the carotid sheath; and a programming wand used externally by the neurologist to adjust stimulation parameters (output current, frequency, pulse width, on/off cycle) at clinic visits. A hand-held magnet allows the patient to immediately trigger an additional stimulation burst when they sense an aura or seizure onset — the magnetically-triggered on-demand mode.

VNS is indicated for patients with drug-resistant focal epilepsy in whom at least two appropriately chosen antiepileptic drug (AED) regimens have failed to control seizures, and who are not surgical candidates for resective brain surgery (either because the seizure focus is not localised, or the focus is in eloquent cortex). VNS is also used in Lennox-Gastaut syndrome with frequent drop attacks. For depression, VNS is approved for adults with treatment-resistant major depressive disorder (MDD) who have failed four or more adequate antidepressant treatment courses. Candidates must have intact left vagus nerve anatomy, no active peptic ulcer disease, no cardiac arrhythmia requiring pacemaker, and must be psychologically suitable for a long-term implantable device. A detailed multidisciplinary epilepsy or psychiatry team assessment is required before proceeding.

Under general anaesthesia, the neurosurgeon makes two incisions: a 5 cm transverse incision below the left clavicle and a 4–5 cm oblique cervical incision at the left neck. The subcutaneous pocket beneath the clavicle accommodates the pulse generator (approximately credit-card sized, weighing 25–30g). Through the cervical incision, the left vagus nerve is carefully identified within the carotid sheath and gently freed from surrounding tissue. The bipolar helical platinum-iridium electrodes are wrapped around the nerve without penetrating it — this non-penetrating design preserves vagal nerve fibres. The electrode lead is tunnelled subcutaneously from the neck to the chest pocket and connected to the generator. The wounds are closed in layers. Total operating time is 60–90 minutes. After a 2-week healing period, stimulation is initiated and gradually titrated upward at clinic visits using a non-invasive laptop-connected programming wand placed over the device. Typical final settings use a current of 0.5–1.5 mA, 500 microsecond pulse width, and 20–30 Hz frequency with a 30-second on / 5-minute off duty cycle. Patients receive a handheld magnet that can be swiped over the device to deliver an additional burst of stimulation during a perceived seizure aura. Initial VNS parameters are set conservatively at implantation; output current is titrated upward at monthly clinic visits over 3-6 months, guided by patient tolerability and seizure diary response, to the optimal therapeutic settings as each patient's response is individually calibrated.

VNS reduces seizure frequency by 50% or more in approximately 50-60% of patients with drug-resistant epilepsy after 12-24 months of treatment, with efficacy increasing progressively over time — response rates at 3 years exceed those at 6 months in published long-term series, supporting patience in assessment. A subset of approximately 5-10% of patients achieve seizure freedom with VNS, most commonly those with focal onset impaired awareness seizures. Beyond seizure frequency reduction, VNS significantly reduces post-ictal duration — the confused, fatigued recovery period after seizures — improving quality of life even in patients who do not achieve a 50% seizure reduction. Seizure-associated SUDEP (sudden unexpected death in epilepsy) risk may be reduced by VNS activation of protective brainstem arousal mechanisms, though this has not been confirmed in controlled trials. In treatment-resistant depression, long-term VNS response rates of 30-55% at 12 months have been reported, with continued improvement over 2-5 years — a temporally distinctive profile from antidepressants, which is consistent with its mechanism of progressive neural circuit remodelling. The AutoStim feature — available in newer-generation AspireSR and SenTiva devices — automatically delivers a stimulation burst in response to cardiac rate increases that accompany seizure onset, providing closed-loop on-demand stimulation without patient action.

The most common side effect is voice alteration — hoarseness or a change in voice quality during stimulation pulses — occurring in 40–55% of patients due to stimulation of the recurrent laryngeal nerve branch of the vagus. This typically diminishes over 6–12 months as the nervous system adapts, or can be reduced by lowering stimulation parameters. Other stimulation-related side effects include cough, throat discomfort, dysphagia, shortness of breath during stimulation bursts, and tingling in the neck. Surgical complications include wound infection (1–3%), haematoma, and rarely left vocal cord paralysis from inadvertent recurrent laryngeal nerve injury (under 1%), causing persistent hoarseness. Horner syndrome (ptosis, miosis, anhidrosis) from sympathetic chain involvement is rare. Battery depletion requires surgical generator replacement every 3–8 years depending on stimulation parameters. MRI is possible with compatible devices under specific safety protocols.

Patients are discharged after overnight or 48-hour observation. Cervical and chest wound healing takes 2–3 weeks; heavy lifting and vigorous neck movements are restricted during this period. Stimulation is activated at the first outpatient clinic visit at 2 weeks post-implantation, starting at low output (0.25 mA) and titrated upward at monthly intervals over 3–6 months. Antiepileptic medications are continued alongside VNS and are not reduced until sustained seizure benefit is established. Device checks and programming are performed every 3–6 months in a specialist VNS clinic. Patients should carry a medical alert card identifying them as a VNS device carrier. Annual battery life assessments guide timely generator replacement before depletion. Patients are instructed to swipe the magnet during aura symptoms, and family members are taught seizure first-aid management.